Reckitt CEO's $17B Predicament Post author:Sam Post published:December 26, 2017 Post category:BioPharma 2018 is the year for Rakesh Kapoor to show he’s worth it. Source: BioSpace You Might Also Like Magellan Diagnostics And Partner To Identify Lead Exposure In Giant Pandas March 16, 2017 Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics September 17, 2017 Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., To Advise Cerevance October 4, 2017
Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics September 17, 2017
